MS & Immune Disorders

Filter Your Results

 

News

 

Fingolimod Effective for Treating Pediatric Patients with Multiple Sclerosis

Thursday, September 13, 2018—Complete results from landmark phase 3 PARADIGMS clinical trial (NCT01892722) were published in the New England Journal of Medicine (September 12, 2018). The PARADIGMS trial i…

Ibudilast Decreases Rate of Brain Atrophy in Progressive MS by 48%

Wednesday, August 29, 2018—Definitive results of a phase 2 study published in the New England Journal of Medicine, show that treatment of patients with progressive multiple sclerosis (MS) ibudilast (MN1…

New Type of Multiple Sclerosis Identified

Tuesday, August 21, 2018—Researchers at the Cleveland Clinic have published findings in Lancet Neurology:(August 21, 2018) of a new subtype of multiple sclerosis, providing further understan…

Funding Received for Phase 2 Trial of Xanomeline-Tropsium Chloride

Wednesday, August 08, 2018—A $42-million financing round has been completed and will be used to finance a phase 2 trial of xanomeline-tropsium chloride (KarXT; Karuna, Boston, MA) for treatment of perso…

New Drug Application for Cladribine Filed and Accepted

Tuesday, July 31, 2018—Cladribine (Mavenclad; EMD Serono, Rockland, MA) is an investigational oral therapy for patients with relapsing forms of multiple sclerosis (MS). The drug has proposed dosing …

Breaching the Blood-Brain Barrier: A Potential New Treatment Modality

Monday, July 30, 2018—In a small, yet groundbreaking, clinical trial, MR-guided focused ultrasound (MRgFUS) (ExablateNeuro; Insightec, Miami FL) was used to open the blood-brain barrier (BBB) safel…

Can Patients Unique Brain Imaging Fingerprints Direct Clinical Management?

Tuesday, July 10, 2018—Researchers for the Alzheimer's Disease Neuroimaging Initiative from the Montreal Neurology Institute and Hospital (Montreal, Canada) have published results in the journal…

Cladribine Tablets Showing Efficacy in Clinical Trials for Patients With Highly Active Multiple Sclerosis

Thursday, June 28, 2018—At the recent CMSC meeting (Nashville, May 30-June 2, 2018)- data from clinical trials from the CLARITY trial of cladribine tablets (investigational in US, marketed as Mavencl…

 
 

Contact Info

For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.

 
  • BRYN MAWR COMMUNICATIONS III, LLC